Tamási Lilla
Semmelweis Egyetem, Pulmonológiai Klinika, Budapest.
Magy Onkol. 2009 Sep;53(3):269-71. doi: 10.1556/MOnkol.53.2009.3.6.
Bisphosphonates are used for supportive treatment in bone metastases of malignant diseases. Advance in various therapeutic options, molecular targeted therapies of malignant diseases result in longer survival, and may bring a higher number of patients surviving until development of secondary lesions, e.g. bone metastases. This review summarizes the antitumor activity of the amino-bisphosphonate zoledronate, describing results of in vitro and animal model studies. Zoledronic acid treatment in patients with malignant solid tumors causing bone metastases prolongs their survival. According to the emerging, until now not too large amount of data, zoledronic acid may have a clinically significant and important direct antitumor activity which is resulted by many pathomechanical pathways summarized in this report. Randomized clinical trials are needed for evaluating real life antitumor activity of amino-bisphosphonates.
双膦酸盐用于恶性疾病骨转移的支持治疗。各种治疗方案的进展，恶性疾病的分子靶向治疗使生存期延长，并可能使更多患者存活至继发病变（如骨转移）出现。本综述总结了氨基双膦酸盐唑来膦酸盐的抗肿瘤活性，描述了体外和动物模型研究的结果。唑来膦酸治疗导致骨转移的恶性实体瘤患者可延长其生存期。根据目前尚不太多的新数据，唑来膦酸可能具有临床上显著且重要的直接抗肿瘤活性，这是由本报告总结的多种病理力学途径所致。需要进行随机临床试验来评估氨基双膦酸盐在实际中的抗肿瘤活性。
